Search

Displaying results 4051 - 4060 of 7607 in total
  1. Drug

    Pyrvinium

    go.drugbank.com/drugs/DB06816
    ApprovedInvestigationalWithdrawn

    Pyrvinium is an anthelmintic effective for pinworms. Several forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and pamoate. Pyrvinum's anti-cancer properties are currently under inves...

  2. Drug

    Relutrigine

    go.drugbank.com/drugs/DB21614
    Investigational

    Relutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine).

  3. Drug

    Tetrahydrocannabivarin

    go.drugbank.com/drugs/DB11755
    Investigational

    Although THCV possesses an almost identical structure to Δ9-THC (varying only by the length of its lipophilic alkyl chain), it has different molecular targets and pharmacological profile [A32972]. … Cannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological

  4. Drug

    CX501

    go.drugbank.com/drugs/DB05174
    Investigational

    It is developed by Cellerix and is in phase I of clinical trials. … Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of

  5. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. … In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.

  6. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    It is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  7. Drug

    Clemastine

    go.drugbank.com/drugs/DB00283
    ApprovedInvestigational

    An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.

  8. Drug

    CX-717

    go.drugbank.com/drugs/DB05047
    IllicitInvestigational

    CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.

  9. Drug

    Zirconium chloride hydroxide

    go.drugbank.com/drugs/DB15479
    ApprovedWithdrawn

    Mixtures: Secret Sporty Clean Antiperspirant Roll-ON
  10. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets.